# Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

> **NCT04802382** · PHASE3 · UNKNOWN · sponsor: **MGC Pharmaceuticals d.o.o** · enrollment: 252 (estimated)

## Conditions studied

- Corona Virus Infection
- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Placebo administration
- **DIAGNOSTIC_TEST:** Confirm SARS-CoV-2 infection
- **PROCEDURE:** Physical Examination
- **PROCEDURE:** Vital Signs
- **DIAGNOSTIC_TEST:** Hematology blood test
- **DIAGNOSTIC_TEST:** Biochemistry blood test
- **OTHER:** NEWS score
- **DIAGNOSTIC_TEST:** PK test
- **DIAGNOSTIC_TEST:** blood test for inflammatory markers
- **DIAGNOSTIC_TEST:** D-dimer test
- **OTHER:** VAS scale
- **DIAGNOSTIC_TEST:** Urine pregnancy test for women of childbearing potential
- **PROCEDURE:** ECG
- **OTHER:** COVID-19-Impact on Quality of Life Questionnaire
- **DRUG:** CimetrA-1
- **DRUG:** CimetrA-2

## Key facts

- **NCT ID:** NCT04802382
- **Lead sponsor:** MGC Pharmaceuticals d.o.o
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-11
- **Primary completion:** 2023-02
- **Final completion:** 2023-04
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802382, "Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04802382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*